SubHero Banner

Ozempic® (semaglutide) – New indication; Rybelsus® (semaglutide) – Label update

January 16, 2020 - Novo Nordisk announced the FDA approval of Ozempic (semaglutide) injection, to reduce the risk of major adverse cardiovascular events (MACE) (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus (T2DM) and established cardiovascular (CV) disease.

Download PDF